A Phase I Study of CD5 CAR-T for Refractory/Relapsed CD5+ T-ALL Patients

Study Summary

This is a phase I, interventional, single arm, open label, clinical study to evaluate the safety and tolerability of CD5 CAR-T cells in refractory/relapsed CD5+ T-ALL patients who have no available curative treatment options.

Interventions

Study Locations

Facility	City	State	Country
Xuanwu Hospital Capital Medical University	Beijing	Beijing Municipality	China

Official Trial Information

View on ClinicalTrials.gov